Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CT and MR Imaging in Colorectal Carcinoma: A Tool for Diagnosis, Staging, Response Evaluation, and Follow-Up.

South Asian journal of cancer·2025
Same author

Regions of homozygosity and a novel variant in Steel syndrome: An added dilemma to diagnosis.

Journal of postgraduate medicine·2023
Same author

Osteopathia Striata with Cranial Sclerosis: A Face-to-Radiograph-to-Gene Diagnosis.

Journal of pediatric genetics·2022
Same author

Pallister-Killian syndrome: Review of fetal phenotype.

Clinical genetics·2018
Same author

Role of magnetic resonance imaging in breast cancer management.

South Asian journal of cancer·2018
Same author

The impact of irrational practices: A wake up call.

Journal of pharmacology & pharmacotherapeutics·2014

Related Experiment Video

Updated: May 27, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Statin intolerance: now a solved problem.

P Sikka1, S Kapoor, V K Bindra

  • 1Department of Pharmacology, LLRM Medical College, Muradnagar, Ghaziabad, India. drpranavsikka@yahoo.com

Journal of Postgraduate Medicine
|November 29, 2011
PubMed
Summary
This summary is machine-generated.

Statin intolerance affects many patients, leading to dyslipidemia and heart risks. Strategies like dose adjustment, alternative drugs, and supplements offer solutions for managing hyperlipidemia safely.

Related Experiment Videos

Last Updated: May 27, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Area of Science:

  • Pharmacology and Cardiology
  • Lipid Metabolism and Cardiovascular Disease

Background:

  • Statins are primary hypolipidemic drugs for dyslipidemia, a key coronary heart disease risk factor.
  • Statin intolerance, due to side effects like hepatotoxicity and myotoxicity, necessitates alternative management strategies.
  • Discontinuation of statins can re-establish dyslipidemia and its associated cardiovascular risks.

Purpose of the Study:

  • To explore strategies for managing hyperlipidemic patients who are intolerant to statins.
  • To identify methods to mitigate statin side effects and ensure continued lipid management.
  • To review alternative hypolipidemic therapies and supportive supplements for statin-intolerant individuals.

Main Methods:

  • Review of potential factors contributing to statin side effects, including drug interactions and patient pathophysiology.
  • Discussion of baseline investigations for liver and muscle toxicity prior to statin initiation.
  • Evaluation of alternative management options: reduced/intermittent statin dosing, alternative drugs, red yeast rice, CoQ10, and vitamin D supplementation.

Main Results:

  • Awareness of drug interactions and personalized dose adjustments can help avoid statin side effects.
  • Several alternative strategies, including lower statin doses, different drug classes, and supplements, are available.
  • Emerging hypolipidemic drugs in clinical trials show promise for statin-intolerant patients.

Conclusions:

  • Effective management of statin intolerance is crucial to prevent recurrent dyslipidemia and cardiovascular events.
  • A combination of careful monitoring, dose optimization, and alternative therapies can ensure lipid control.
  • Further research into novel hypolipidemic agents is essential for expanding treatment options.